Tag: treatment
Effect of Tocilizumab vs. Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
The administration of tocilizumab in patients with COVID-19 pneumonia and a Pao2/Fio2 ratio between 200 and 300 mm Hg did not reduce the risk of clinical worsening. Further blinded, placebo-controlled randomized clinical... read more
Dr. Fauci Headlines COVID-19-focused Opening Session at CHEST 2020
The COVID-19 pandemic upended the practices and lives of CHEST members—and changed CHEST 2020 into a virtual meeting—so it's fitting that this year's Opening Session focused on the defining global event of the year. Anthony... read more
Balancing Intervention and Inaction During the COVID-19 Pandemic
More than 38 million people worldwide have been infected with the severe acute respiratory syndrome (SARS) coronavirus 2, creating intense pressure on clinicians to offer state-of-the-art, life-saving treatment to patients. The... read more
VTE and COVID-19: Would you like to know more?
Who wouldn't want to know more about a disease that has killed >1 million people to date, worldwide. Who wouldn't want to know more about the thromboembolic risk associated with COVID-19 when we have been told that the VTE... read more
Extracorporeal Cytokine Adsorption as an Alternative to Pharmacological Inhibition of IL-6 in COVID-19
With great interest we read the article by Convertino et al. discussing potential treatment targets for pharmacological immunomodulation in coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS).... read more
Thrombosis and Bleeding in ECMO without Anticoagulation
Extracorporeal membrane oxygenation (ECMO) causes both thrombosis and bleeding. Major society guidelines recommend continuous, systemic anticoagulation to prevent thrombosis of the ECMO circuit, though this may be undesirable... read more
TEG for Hypocoagulable Patients with Non-Traumatic Bleeding
Thromboelastogram (TEG) has been extensively studied in trauma and surgical patients, but has not been well studied in nontraumatic bleeding, nor has its use been well evaluated in the emergency department. This study... read more
Mortality Outcomes with Hydroxychloroquine and Chloroquine in COVID-19
No benefit of hydroxychloroquine or chloroquine on the survival of COVID-19 patients found. For hydroxychloroquine, the confidence interval is compatible with increased mortality or negligibly reduced mortality. Findings... read more
Fibrin-derived Peptide as Salvage Treatment in Critically Ill Patients with COVID-19-associated ARDS
After SARS-CoV-2 first occurred in China in December of 2019, it set out to become a global pandemic. Critically ill patients constitute about 2–9% of all infected patients and progress from pneumonia and hypoxemia to multi-organ... read more
Advances In ICU Care Are Saving More Patients Who Have COVID-19
One thing that has improved a lot over the course of the pandemic is treatment of seriously ill COVID-19 patients in intensive care units. Here's one man's success story. If you think all the coronavirus news is bad, consider... read more
VA-ECMO to Rescue Sepsis-induced Cardiogenic Shock
Patients with sepsis-induced cardiomyopathy with cardiogenic shock have a high mortality. This study assessed venoarterial extracorporeal membrane oxygenation (VA-ECMO) support for sepsis-induced cardiogenic shock refractory... read more
From Russia with Love – “Sputnik V” COVID-19 Vaccine Generated an Immune Response
Between June 18 and Aug 3, 2020, Ministry of Health of the Russian Federation enrolled 76 participants to the two studies (38 in each study). In each study, 9 volunteers received rAd26-S in Phase 1, nine received rAd5-S in... read more
COVID-19: A Critical Analysis of Chloroquine and Hydroxychloroquine Clinical Pharmacology
Chloroquine and hydroxychloroquine have been used for over 60 years in the treatment of malaria, amoebic liver abscess, and several rheumatological conditions, but their clinical pharmacology is not well understood. COVID-19... read more
Hydroxychloroquine With or Without Azithromycin
Among patients hospitalized with mild-to-moderate COVID-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. A total of 667 patients... read more
Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19
Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority... read more
